Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 4Irinotecan 4eribulin 2Topotecan 2LY2940680 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1surufatinib 1sonidegib 1soblidotin 1ribociclib 1regorafenib 1pegfilgrastim 1palbociclib 1omburtamab I-131 1lenvatinib 1iso-sulfan blue 1dostarlimab 1dinutuximab 1copanlisib 1cixutumumab 1ceritinib 1bempegaldesleukin 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Vincristine 1Pemetrexed 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rhabdomyosarcoma × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡